![ISPOR Europe 2024 – May 5-8. Register now.]({"type":"image" , "src" : "/sda/112342/JournalAd-ISPOR-2024-Leaderboard.jpg"})
Citations (36)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (9)
L. Klimek, R. Brehler, R. Mösges, P. Demoly, J. Mullol, D. Y. Wang, R. E. O’Hehir, A. Didier, M. Kopp, C. Bos & E. Karagiannis. (2022) Update about Oralair® as a treatment for grass pollen allergic rhinitis. Human Vaccines & Immunotherapeutics 18:5.
Read now
Read now
Carlo Cavaliere, Cristoforo Incorvaia, Elona Begvarfaj, Maria Patrizia Orlando, Rosaria Turchetta, Angela Musacchio, Massimo Ralli, Andrea Ciofalo, Antonio Greco, Marco de Vincentiis & Simonetta Masieri. (2021) The safety of sublingual immunotherapy, can the rare systemic reactions be prevented?. Expert Opinion on Drug Safety 20:3, pages 259-264.
Read now
Read now
Philippe Devillier, Pascal Demoly & Mathieu Molimard. (2020) Allergen immunotherapy: what is the added value of real-world evidence from retrospective claims database studies?. Expert Review of Respiratory Medicine 14:5, pages 445-452.
Read now
Read now
Giorgio Walter Canonica, Philippe Devillier, Thomas Casale, Pascal Demoly, Catherine Bos, Efstrathios Karagiannis, Giovanni Passalacqua, Ulrich Wahn & Laurent Mascarell. (2019) Clinical efficacy of sublingual immunotherapy tablets for allergic rhinitis is unlikely to be derived from in vitro allergen-release data. Expert Review of Clinical Immunology 15:9, pages 921-928.
Read now
Read now
Cristoforo Incorvaia, Bruna L. Gritti & Erminia Ridolo. (2018) The economic advantage of allergen immunotherapy over drug treatment in respiratory allergy. Journal of Medical Economics 21:6, pages 553-555.
Read now
Read now
Philippe Devillier, Ulrich Wahn, Stefan Zielen & Joachim Heinrich. (2017) Grass pollen sublingual immunotherapy tablets provide long-term relief of grass pollen-associated allergic rhinitis and reduce the risk of asthma: findings from a retrospective, real-world database subanalysis. Expert Review of Clinical Immunology 13:12, pages 1199-1206.
Read now
Read now
Olivia Larsson, Laila Hellkvist, Ulla Peterson-Westin & Lars Olaf Cardell. (2016) Novel strategies for the treatment of grass pollen-induced allergic rhinitis. Expert Opinion on Biological Therapy 16:9, pages 1143-1150.
Read now
Read now
Giorgio Ciprandi, Gian Luigi Marseglia, Riccardo Castagnoli, Chiara Valsecchi, Carlotta Tagliacarne, Silvia Caimmi & Amelia Licari. (2015) From IgE to clinical trials of allergic rhinitis. Expert Review of Clinical Immunology 11:12, pages 1321-1333.
Read now
Read now
Alain Didier & Brigitte Bons. (2015) Safety and tolerability of 5-grass pollen tablet sublingual immunotherapy: pooled analysis and clinical review. Expert Opinion on Drug Safety 14:5, pages 777-788.
Read now
Read now
Articles from other publishers (27)
Lucía González-Bravo, Jimena Laiseca García, Martina Privitera & Ana Rosado. (2023) Off-label Use of Oral Immunotherapy for Rhinoconjunctivitis and Asthma
due to Grass Pollen: A Safe and Effective Alternative in Patients over 65
Years Old: A Series of Case Reports. Current Drug Safety 18:4, pages 599-602.
Crossref
Crossref
Lawrence DuBuske. (2022) Efficacy and safety of sublingual allergen immunotherapy. Allergy and Asthma Proceedings 43:4, pages 272-280.
Crossref
Crossref
Sheryl A. van Nunen, Melanie B. Burk, Pamela K. Burton, Geoffrey Ford, Richard J. Harvey, Alexander Lozynsky, Elizabeth Pickford, Janet S. Rimmer, Joanne Smart, Michael F. Sutherland, Francis Thien, Heinrich C. Weber, Harry Zehnwirth, Ed Newbigin & Constance H. Katelaris. (2022) 5-grass-pollen SLIT effectiveness in seasonal allergic rhinitis: Impact of sensitization to subtropical grass pollen. World Allergy Organization Journal 15:2, pages 100632.
Crossref
Crossref
Felicity Huang, David H. Wang, Chuan T. Foo, Alan C. Young, Jie Shen Fok & Francis Thien. (2022) The Melbourne epidemic thunderstorm asthma event 2016: a 5-year longitudinal study. Asia Pacific Allergy 12:4.
Crossref
Crossref
Sanny K. Chan. (2019) Advances in aeroallergen immunotherapy. Current Opinion in Pediatrics 31:6, pages 828-834.
Crossref
Crossref
Philippe Devillier, Mathieu Molimard, Xavier Ansolabehere, Isabelle Bardoulat, Nicolas Coulombel, Frédérique Maurel, Philippe Le Jeunne & Pascal Demoly. (2019) Immunotherapy with grass pollen tablets reduces medication dispensing for allergic rhinitis and asthma: A retrospective database study in France. Allergy.
Crossref
Crossref
C. Marcot, F. de Blay, L. Guilleminault, A. Didier, G. de Bonnecaze, A. Magnan, L. de Gabory, G. Mortuaire, A. Thillay, F. Amat, N. Leboulanger, V. Prulière-Escabasse, V. Favier, L. Crampette, E. Serrano, J. Michel & V. Mercier. 2019. Rhinites Allergiques. Rhinites Allergiques
101
135
.
Irena Krčmová & Jakub Novosad. (2018) Modern aspects of allergic rhinitis. Interní medicína pro praxi 20:2, pages 74-80.
Crossref
Crossref
S. Zielen, P. Devillier, J. Heinrich, H. Richter & U. Wahn. (2017) Sublingual immunotherapy provides long‐term relief in allergic rhinitis and reduces the risk of asthma: A retrospective, real‐world database analysis. Allergy 73:1, pages 165-177.
Crossref
Crossref
Ralph Mösges, Christina Rohdenburg, Andrea Eichel, Gregor Zadoyan, Elena-Manja Kasche, Kija Shah-Hosseini, Walter Lehmacher, Petra Schmalz & Enrico Compalati. (2017) Dose-finding study of carbamylated monomeric allergoid tablets in grass-allergic rhinoconjunctivitis patients. Immunotherapy 9:15, pages 1225-1238.
Crossref
Crossref
G. Mortuaire, J. Michel, J.F. Papon, O. Malard, D. Ebbo, L. Crampette, R. Jankowski, A. Coste & E. Serrano. (2017) Specific immunotherapy in allergic rhinitis. European Annals of Otorhinolaryngology, Head and Neck Diseases 134:4, pages 253-258.
Crossref
Crossref
G. Mortuaire, J. Michel, J.-F. Papon, O. Malard, D. Ebbo, L. Crampette, R. Jankowski, A. Coste & E. Serrano. (2017) L’immunotherapie antiallergenique dans la rhinite allergique. Annales françaises d'Oto-rhino-laryngologie et de Pathologie Cervico-faciale 134:4, pages 247-253.
Crossref
Crossref
Anne K. Ellis, Charles W. Frankish, Robyn E. O'Hehir, Kristen Armstrong, Lisa Steacy, Mark Larché & Roderick P. Hafner. (2017) Treatment with grass allergen peptides improves symptoms of grass pollen–induced allergic rhinoconjunctivitis. Journal of Allergy and Clinical Immunology 140:2, pages 486-496.
Crossref
Crossref
Kija Shah-Hosseini, Eva-Maria Krudewig, Meike Hadler, Efstrathios Karagiannis & Ralph Mösges. (2017) Management of Grass Pollen Allergy with 5-Grass Pollen Tablet: Results of a 2-Year Real-Life Study. Advances in Therapy 34:6, pages 1382-1397.
Crossref
Crossref
Vít Petrů. (2017) Allergen immunotherapy - an update. Interní medicína pro praxi 19:2, pages 78-81.
Crossref
Crossref
Jay Portnoy & Linda S. Cox. (2017) Is the Benefit From Prescribing Epinephrine Autoinjectors for Sublingual Immunotherapy Worth the Cost? Lessons Learned From Clinical Trials. The Journal of Allergy and Clinical Immunology: In Practice 5:1, pages 90-91.
Crossref
Crossref
M. C. Matheson, J. C. Reece, R. K. Kandane-Rathnayake, M. L. K. Tang, J. A. Simpson, I. H. Feather, M. C. Southey, H. Tsimiklis, J. L. Hopper, S. C. Morrison, G. G. Giles, E. H. Walters & S. C. Dharmage. (2016) Mould-sensitized adults have lower Th2 cytokines and a higher prevalence of asthma than those sensitized to other aeroallergens. Allergy 71:12, pages 1701-1711.
Crossref
Crossref
Efren Rael. (2016) Allergen Immunotherapy. Primary Care: Clinics in Office Practice 43:3, pages 487-494.
Crossref
Crossref
Liesbeth Ras, Hans de Groot, Cornelis H.M. Stengs & Ranny van Weissenbruch. (2016) Persistence of treatment with 5-grass pollen tablets in patients with allergic rhinitis: a real-life study. Annals of Allergy, Asthma & Immunology 116:1, pages 52-58.e2.
Crossref
Crossref
K S Pavlova & O M Kurbacheva. (2015) Current strategies of allergen-specific immunotherapy. Russian Journal of Allergy 12:4, pages 16-26.
Crossref
Crossref
F. Hannachi, P. Demoly, A.M. Chiriac, J.-L. Bourrain, H. Dhivert-Donnadieu, D. Costa, M. Amouyal & B. Folco-Lognos. (2015) La place, en médecine générale, des nouveaux traitements d’immunothérapie allergénique sublinguale aux pollens de graminées chez les patients souffrant d’allergies respiratoires. Revue Française d'Allergologie 55:8, pages 506-516.
Crossref
Crossref
Anusha Vadlamudi & Marcus Shaker. (2015) New developments in allergen immunotherapy. Current Opinion in Pediatrics 27:5, pages 649-655.
Crossref
Crossref
Rosa B. Lipin & Sarah K. Wise. (2015) SLIT Tablets for Polysensitized Allergic Rhinitis. Current Otorhinolaryngology Reports 3:3, pages 180-185.
Crossref
Crossref
Nicole Pleskovic, Ashton Bartholow, Deborah A. Gentile & David P. Skoner. (2015) The Future of Sublingual Immunotherapy in the United States. Current Allergy and Asthma Reports 15:8.
Crossref
Crossref
Pascal Demoly, Moises A Calderon, Thomas B Casale, Hans‐Jørgen Malling & Ulrich Wahn. (2015) “The value of pre‐ and co‐seasonal sublingual immunotherapy in pollen‐induced allergic rhinoconjunctivitis”. Clinical and Translational Allergy 5:1, pages 18.
Crossref
Crossref
Alain Didier, Hans‐Jørgen Malling, Margitta Worm, Friedrich Horak & Gordon L Sussman. (2015) Prolonged efficacy of the 300IR 5‐grass pollen tablet up to 2 years after treatment cessation, as measured by a recommended daily combined score. Clinical and Translational Allergy 5:1, pages 12.
Crossref
Crossref
Tarik Yalaoui & Olivier de Beaumont. (2014) Comments on: ‘Anaphylaxis caused by in‐season switchover of sublingual immunotherapy formulation’. Pediatric Allergy and Immunology 25:7, pages 715-716.
Crossref
Crossref